Orchard Therapeutics announced the Swiss Agency for Therapeutic Products has approved Libmeldy a hematopoietic stem cell gene therapy, for the treatment of early-onset metachromatic leukodystrophy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ORTX:
- Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLD
- Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH
- Orchard Therapeutics receives U.S. fast track designation for OTL-203
- Orchard Therapeutics reports Q3 EPS (15c), consensus (75c)
- Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments